Evidence map›Paper›PMID 40706589›Full record

ArticleCell reports. Medicine2025

Neolactotetraosylceramide enables urinary detection of bladder cancer.

Inês B Moreira, Charlotte Rossdam, Jonas Kaynert, Julia Beimdiek, Manuel M Vicente, Jessica Schmitz, Anika Großhennig, Astrid Oberbeck, Michèle J Hoffmann, Michele E Rosero Moreno and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Inês B MoreiraInstitute of Clinical Biochemistry, Hannover Medical School, 30625 Hannover, Germany.
Charlotte RossdamInstitute of Clinical Biochemistry, Hannover Medical School, 30625 Hannover, Germany; Proteomics, Institute of Theoretical Medicine, Faculty of Medicine, University of Augsburg, 86159 Augsburg, Germany.
Jonas KaynertInstitute of Clinical Biochemistry, Hannover Medical School, 30625 Hannover, Germany.
Julia BeimdiekInstitute of Clinical Biochemistry, Hannover Medical School, 30625 Hannover, Germany; Proteomics, Institute of Theoretical Medicine, Faculty of Medicine, University of Augsburg, 86159 Augsburg, Germany.
Manuel M VicenteInstitute of Clinical Biochemistry, Hannover Medical School, 30625 Hannover, Germany.
Jessica SchmitzInstitute for Pathology, Nephropathology Unit, Hannover Medical School, 30625 Hannover, Germany.
Anika GroßhennigInstitute of Biostatistics, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.
Astrid OberbeckInstitute of Clinical Biochemistry, Hannover Medical School, 30625 Hannover, Germany.
Michèle J HoffmannDepartment of Urology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
Michele E Rosero MorenoDepartment of Urology, Jena University Hospital, Friedrich-Schiller University, 07747 Jena, Germany.
Daniel SteinbachDepartment of Urology, Jena University Hospital, Friedrich-Schiller University, 07747 Jena, Germany.
Maria L BarcenaDepartment of Urology, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany.
Yannick LippkaDepartment of Urology, KRH Klinikum Siloah, 30449 Hannover, Germany.
Jan H BräsenInstitute for Pathology, Nephropathology Unit, Hannover Medical School, 30625 Hannover, Germany.
Hossein TezvalDepartment of Urology and Urologic Oncology, Hannover Medical School, 30625 Hannover, Germany.
Falk F R BuettnerInstitute of Clinical Biochemistry, Hannover Medical School, 30625 Hannover, Germany; Proteomics, Institute of Theoretical Medicine, Faculty of Medicine, University of Augsburg, 86159 Augsburg, Germany. Electronic address: buettner.falk@mh-hannover.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycosphingolipids (GSLs) are promising cancer biomarkers. Using multiplexed capillary gel-electrophoresis with laser-induced fluorescence detection (xCGE-LIF), we profile GSLs in bladder cancer (BC) tissues and find a significant increase in neolactotetraosylceramide (nLc4) compared to matched normal tissue (n = 30). Immunofluorescence confirms tumor-specific nLc4 expression in both non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC), colocalizing with luminal and basal urothelial markers. Analysis of paired tissue/urine samples, along with BC cell lines, reveals secretion of nLc4 associated with extracellular vesicles in MIBC. Urine profiling shows elevated nLc4 levels in BC patients (n = 16) versus controls (n = 50; area under the curve [AUC] 0.75; accuracy 82%). To support clinical translation, we apply an anti-nLc4 ELISA in a discovery cohort (n = 18) and a multi-center validation cohort (n = 123). In the validation set, urinary nLc4 levels are significantly elevated in MIBC (AUC 0.78; accuracy 64%) and increase with disease severity. These findings support the potential of urinary nLc4 as a non-invasive biomarker for BC detection.

Indexed as

Biomarkers, TumorUrinary Bladder NeoplasmsAgedCell Line, TumorExtracellular VesiclesFemaleGlycosphingolipidsHumansMaleMiddle AgedBiomarkers, TumorGlycosphingolipidsbladder cancerextracellular vesiclesglycosphingolipidsliquid biopsyneolactotetraoscylceramidenLc4tumor glycosylationurinary biomarkersxCGE-LIF

Identifiers

PMID40706589
PMCPMC12432384

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.